Shire acquires Foresight Biotherapeutics, rights to late-stage drug FST-100.
- Published in:
- Optometry Times, 2015, v. 7, n. 9, p. 23
- Publication type:
- Article
Works matching DE "SHIRE PLC"
Results: 24
1
2
Shire acquires NPS Pharmaceuticals for $5.2 billion.
- Published in:
- Optometry Times, 2015, v. 7, n. 2, p. 18
- Publication type:
- Article
3
PsychRx.
- Published in:
- Psychiatry (1550-5952), 2010, v. 7, n. 5, p. 9
- Publication type:
- Article
4
SHIRE ANNOUNCES PUBLICATION OF OPEN-LABEL STUDY ON COADMINISTRATION OF INTUNIV (GUANFACINE) EXTENDED-RELEASE TABLETS WITH STIMULANTS.
- Published in:
- Psychiatry (1550-5952), 2009, v. 6, n. 11, p. 10
- Publication type:
- Article
5
FDA ISSUES COMPLETE RESPONSE LETTER FOR INTUNIV (GUANFACINE) EXTENDED RELEASE FOR THE TREATMENT OF ADHD IN CHILDREN AND ADOLESCENTS.
- Published in:
- Psychiatry (1550-5952), 2009, v. 6, n. 8, p. 40
- Publication type:
- Article
6
STUDY SHOWED VYVANSE CII PROVIDED SIGNIFICANT EFFICACY AT 14 HOURS AFTER ADMINISTRATION IN ADULTS WITH ADHD IN AN ADULT SIMULATED WORKPLACE ENVIRONMENT.
- Published in:
- Psychiatry (1550-5952), 2009, v. 6, n. 7, p. 50
- Publication type:
- Article
7
FDA APPROVES LABELING CHANGE FOR VYVANSE (LISDEXAMFETAMINE DIMESYLATE) CII TO INCLUDE SUPPLEMENTARY CLINICAL DATA SUPPORTING EFFICACY AT 13 HOURS POSTDOSE IN CHILDREN AGED 6 TO 12 WITH ADHD.
- Published in:
- Psychiatry (1550-5952), 2009, v. 6, n. 6, p. 11
- Publication type:
- Article
8
Seven days: 8-14 November 2013.
- Published in:
- Nature, 2013, v. 503, n. 7475, p. 170, doi. 10.1038/503170a
- Publication type:
- Article
9
Shire OK'd for dry eye, gives ODs more options.
- Published in:
- Optometry Times, 2016, v. 8, n. 8, p. 1
- By:
- Publication type:
- Article
10
Shire resubmits NDA for lifitegrast.
- Published in:
- Optometry Times, 2016, v. 8, n. 2, p. 17
- Publication type:
- Article
11
Shire to resubmit lifitegrast to FDA in 2016 after new study results.
- Published in:
- Optometry Times, 2015, v. 7, n. 11, p. 24
- Publication type:
- Article
12
Business digest.
- Published in:
- Chemistry & Industry, 2016, v. 80, n. 6, p. 12, doi. 10.1002/cind.806_3.x
- Publication type:
- Article
13
Takeda and Shire agree £46bn takeover.
- Published in:
- TCE: The Chemical Engineer, 2018, n. 924, p. 17
- Publication type:
- Article
14
Takeda mulls bid for Shire.
- Published in:
- TCE: The Chemical Engineer, 2018, n. 923, p. 19
- Publication type:
- Article
15
Deal watch: Shire increases focus on regenerative medicine.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 6, p. 430, doi. 10.1038/nrd3767
- By:
- Publication type:
- Article
16
Deal watch: Acceleron and Shire to target the activin receptor pathway for muscular disorders.
- Published in:
- 2010
- Publication type:
- journal article
17
Shire submits European marketing authorization application for velaglucerase a for the treatment of type 1 Gaucher's Disease.
- Published in:
- Expert Review of Endocrinology & Metabolism, 2010, v. 5, n. 1, p. 4
- Publication type:
- Article
18
A powerhouse first month for a new FDA.
- Published in:
- Contemporary Pediatrics, 2009, v. 26, n. 7, p. 16
- By:
- Publication type:
- Article
19
Biotechs recoil at hedge fund manager's patent attacks.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 7, p. 680, doi. 10.1038/nbt0715-680b
- By:
- Publication type:
- Article
20
Shire punts on bioscaffolds for cell-based regenerative medicine.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 8, p. 727, doi. 10.1038/nbt0812-727
- By:
- Publication type:
- Article
21
Business digest.
- Published in:
- Chemistry & Industry, 2013, v. 77, n. 5, p. 19
- Publication type:
- Article
22
Movers & Shakers.
- Published in:
- Chemistry & Industry, 2012, v. 76, n. 10, p. 42, doi. 10.1002/cind.7610_12.x
- Publication type:
- Article
23
From the FDA.
- Published in:
- Brown University Child & Adolescent Psychopharmacology Update, 2009, v. 11, n. 12, p. 8
- Publication type:
- Article
24
Shire's replacement enzymes validate gene activation.
- Published in:
- Nature Biotechnology, 2010, v. 28, n. 11, p. 1139, doi. 10.1038/nbt1110-1139a
- By:
- Publication type:
- Article